Vasodilatation Induced by Beta 2 Adrenergic Receptor Activation Is Impaired in Obese Hypertensives Before and After Weight Loss: 9C.03

Abstract

Evidence from experimental studies suggest that renalase, a soluble FAD-dependent protein, is involved in blood pressure regulation, possibly via degradation of catecholamines including noradrenaline. To investigate whether renalase is associated with blood pressure levels and/or indices of noradrenaline disposition in humans we studied a cohort of 22 patients with resistant hypertension (at least 3 antihypertensive drugs including a diuretic) and 4 healthy, normotensive control subjects. Radiotracer dilution methodology and arterial blood sampling was applied to measure whole body noradrenaline (NA) spillover. Arterial plasma levels of renalase were measured by Western blot analysis using a monoclonal anti-renalase antibody and quantified using a gel documentation system (Bio-Rad Quantity One Software). Split half analysis of the hypertensive cohort according to systolic blood pressure levels (mean: 186 AE 22 vs 156 AE 9mmHg; p < 0.001) revealed that mean arterial renalase levels were substantially lower in the group with higher systolic blood pressure (62 AE 31 vs 125 AE 82 arbitrary units; p < 0.05), whereas whole body NA spillover tended to be higher in the group with higher systolic blood pressure without reaching statistical significance (645 AE 445 vs 407 AE 195ng/min; p = 0.12). Arterial renalase levels were higher (238 AE 174 arbitrary units) and whole body NA spillover was lower (168 AE 78ng/min) in the normotensive control subjects (mean systolic blood pressure: 123 AE 7mmHg)(all p < 0.05). Correlation analysis revealed an inverse relationship between arterial renalase plasma levels and systolic blood pressure for the entire cohort (r = -0.52; p < 0.05). These data suggest that arterial plasma levels of renalase are inversely associated with systolic blood pressure in a cohort of patients with resistant hypertension. Whether this relation can in part be explained by alleviated degradation of noradrenaline or whether alternative pathways are involved requires further investigation.Objective: Essential hypertension is characterized by a marked sympathetic activation, which is coupled with an impairment of baroreceptor-heart rate control. Whether the behaviour of sympathetic and baroreceptor function is peculiar of the established hypertensive state or it does also characterize the so-called high-normal blood pressure (BP) state is unknown, however.Design and Methods: In 12 subjects with optimal BP (O, age: 38.1 AE 2.1 years, mean AE SEM), 10 with normal BP (N) and 9 with high-normal BP (HN, ESH guidelines classification), all age-matched with O, we measured beat-to-beat arterial BP (Finapres), heart rate (HR, EKG), plasma norepinephrine (NE, venous sample, HPLC) and muscle sympathetic nerve traffic (MSNA, microneurography peroneal nerve) at rest and during baroreceptor stimulation and deactivation (vasoactive drug infusion technique). Measurements also included anthropometric as well as metabolic parameters, such as HOMA index.Results: Body mass index,waist circumference and HOMA index were slightly, alt...

Reduction in CgA-Derived CST Protein Level in HTR-8/SVneo and BeWo Trophoblastic Cell Lines Caused by the Preeclamptic Environment

“…Activation of the β2 receptor results in increased vasodilation via endothelium-dependent and -independent mechanisms [ 44 ]; this is accompanied by a reduction in β-adrenergic-mediated responses in hypertension [ 45 ], and a lower number of functional β2-adrenoceptors in PE [ 46 ]. Hence, the protective, anti-apoptotic effect of CST may be diminished in PE patients, resulting in a higher percentage of apoptotic cells.…”

Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications

“…We have shown that orlistat decreases sympathetic nerve traffic by 20% in obese normotensive 139 and by 26% in obese hypertensive subjects. 140 Most patients have sustained weight loss with orlistat, with a ‘failure’ rate (defined as < 5% weight loss at 12 months) of 51% compared with 77% for placebo. 132 Overall, orlistat reduces weight by ~3% and BP by ~2 mm Hg, additional to what is achieved with lifestyle intervention.…”

The Role of Catestatin in Preeclampsia

“…Additionally, another in vitro study confirming the anti-apoptotic function of CST found it can regulate the PI3K/Akt signaling pathway by activating the beta 2 adrenergic (β2) receptor [ 81 ]. Although the activation of β2 receptors typically results in vasodilatation [ 82 ], it can induce an observable reduction in β2-mediated responses in hypertension and lower the number of functional β2-adrenoceptors in PE [ 83 , 84 ].…”